Trials / Completed
CompletedNCT04698642
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 2a)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based on the results from Phase 1 of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBL-514 | Both sides of the abdominal region will receive CBL-514. |
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
- First posted
- 2021-01-07
- Last updated
- 2021-01-08
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04698642. Inclusion in this directory is not an endorsement.